Clinical-stage neuroscience company developing non-hallucinogenic neuroplastogens (psychoplastogens) for mental-health disorders, based on research by co-founder David E. Olson at UC Davis. Its lead candidate DLX-001 (zalsupindole) is an oral non-hallucinogenic compound for depression that showed a favorable safety and tolerability profile with no hallucinatory or dissociative effects in Phase 1; the company has synthesized over 2,000 novel psychoplastogens.
Delix Therapeutics News 10 articles
- Delix reports positive Phase 1b data for non-hallucinogenic DLX-001 and FDA clearance of at-home Phase 2
- Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001
- Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer
- Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer
- Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001
- Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity
- Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability
- Delix Therapeutics Expands World-Class Team with First Head of R&D
- Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
- Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders